SOURCE: BioMedReports


February 02, 2012 08:35 ET

OncoSec's President and CEO Explains His Firm's Ambitious List of Milestones for 2012

LOS ANGELES, CA--(Marketwire - Feb 2, 2012) - In an exclusive interview with BioMedReports, Punit Dhillon, the President and CEO of OncoSec Medical Inc. (OTCBB: ONCS), explains some of the reasons why investors may be taking positions in the company after a slow but steady sell-off in the market.

In March of 2011, Mr. Dhillon became president and chief executive officer after co-founding the firm and as we discuss in his candid interview, OncoSec is currently initiating three Phase 2 clinical trials in metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. All three of these trials are being held under a physician Investigational New Drug (IND) application. This regulatory path has allowed OncoSec to enter the clinic and quickly obtain clinical catalysts. The Company will leverage data from these studies to initiate our own sponsor IND in 2012.

The full exclusive Q&A is available now at:

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades during these volatile markets can go to:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556